JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors
Status:
Completed
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
JTX-2011-101 is a Phase 1/2, open label, dose escalation and expansion clinical study of
JTX-2011 alone and in combination with nivolumab, ipilimumab, or pembrolizumab in adult
subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated
dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.